A discharge petition for the Prescription Drug Fairness for Seniors Act has been issued by the Democratic members of the House of Representatives. The petition, which seeks to circumvent the committee system for the bill, had 144 signatures as of press time, short of the 218 votes needed to get the bill out of committee.
A discharge petition for the Prescription Drug Fairness for Seniors Act has been issued by the Democratic members of the House of Representatives. The petition, which seeks to circumvent the committee system for the bill, had 144 signatures as of press time, short of the 218 votes needed to get the bill out of committee.
The petition has come under fire from many House Democrats. "Discharging [the bill] to the floor would preclude consideration of a full range of solutions," read a "Dear Democratic Colleague" letter co written by Rush Holt (D-NJ) and Adam Smith (D-WA). "We expect it would only heighten the partisan debate on an issue too important to our seniors. We need action.... Signing a discharge petition could short-circuit the consideration of ideas on the very prescription drug benefit that each of us hopes to achieve this year."
If passed, the Prescription Drug Fairness for Seniors Act would require that retail pharmacies selling to senior citizens be given the same discount schedule, between 24 and 40%, that the U.S. government is given for their health agencies and clinics.
The bill itself has been criticized because it does not actually require the pharmacies it extends discounts to to pass those savings on to their customers. Said Reps. David Price (D-NC) and Calvin Dooly (D-CA) in their "Dear Democratic Colleague" letter, "Pharmacies could use the VA discount to subsidize the price of candy or toilet paper, or they could give lower prices to seniors. Nothing in the bill even requires the pharmacies to pass the savings along to anyone. The pharmacy could legally use the discount to improve profits." PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.